[1]
|
Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R. and Fletcher, A.A. (1922) Pancreatic Extracts in the Treatment of Diabetes Mellitus. Canadian Medical Association Journal, 12, 141-146.
|
[2]
|
Banting, F.G., Campbell, W.R. and Fletcher, A.A. (1923) Further Clinical Experience with Insulin (Pancreatic Extracts) in the Treatment of Diabetes Mellitus. BMJ, 1, 8-12. https://doi.org/10.1136/bmj.1.3236.8
|
[3]
|
Diabetes, C., Complications Trial Research, G., Nathan, D.M., Genuth, S., Lachin, J., Cleary, P., Crofford, O., Davis, M., Rand, L. and Siebert, C. (1993) The Effect of intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. The New England Journal of Medicine, 329, 977-986. https://doi.org/10.1056/NEJM199309303291401
|
[4]
|
Miller, R.G., Secrest, A.M., Sharma, R.K., Songer, T.J. and Orchard, T.J. (2012) Improvements in the Life Expectancy of Type 1 Diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study Cohort. Diabetes, 61, 2987-2992. https://doi.org/10.2337/db11-1625
|
[5]
|
Heald, A.H., Stedman, M., Davies, M., Livingston, M., Alshames, R., Lunt, M., Rayman, G. and Gadsby, R. (2020) Estimating Life Years Lost to Diabetes: Outcomes from Analysis of National Diabetes Audit and Office of National Statistics Data. Cardiovascular Endocrinology & Metabolism, 9, 183-185. https://doi.org/10.1097/XCE.0000000000000210
|
[6]
|
The DCCT Research Group (1991) Epidemiology of Severe Hypoglycemia in the Diabetes Control and Complications Trial. The American Journal of Medicine, 90, 450-459. https://doi.org/10.1016/0002-9343(91)90605-W
|
[7]
|
Diabetes Control and Complications Trial Research Group (1994) Effect of Intensive Diabetes Treatment on the Development and Progression of Long-Term Complications in Adolescents with Insulin-Dependent Diabetes Mellitus: Diabetes Control and Complications Trial. The Journal of Pediatrics, 125, 177-188. https://doi.org/10.1016/S0022-3476(94)70190-3
|
[8]
|
The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes, 46, 271-286. https://doi.org/10.2337/diab.46.2.271
|
[9]
|
Cengiz, E., Xing, D., Wong, J.C., Wolfsdorf, J.I., Haymond, M.W., Rewers, A., Shanmugham, S., Tamborlane, W.V., Willi, S.M., Seiple, D.L., et al. (2013) Severe Hypoglycemia and Diabetic Ketoacidosis among Youth with Type 1 Diabetes in the T1D Exchange Clinic Registry. Pediatric Diabetes, 14, 447-454. https://doi.org/10.1111/pedi.12030
|
[10]
|
Brazeau, A.S., Rabasa-Lhoret, R., Strychar, I. and Mircescu, H. (2008) Barriers to Physical Activity among Patients with Type 1 Diabetes. Diabetes Care, 31, 2108-2109. https://doi.org/10.2337/dc08-0720
|
[11]
|
Roberts, A.J., Taplin, C.E., Isom, S., Divers, J., Saydah, S., Jensen, E.T., Mayer-Davis, E.J., Reid, L.A., Liese, A.D., Dolan, L.M., et al. (2020) Association between Fear of Hypoglycemia and Physical Activity in Youth with Type 1 Diabetes: The SEARCH for Diabetes in Youth Study. Pediatric Diabetes, 21, 1277-1284. https://doi.org/10.1111/pedi.13092
|
[12]
|
Jabbour, G., Henderson, M. and Mathieu, M.E. (2016) Barriers to Active Lifestyles in Children with Type 1 Diabetes. The Canadian Journal of Diabetes, 40, 170-172. https://doi.org/10.1016/j.jcjd.2015.12.001
|
[13]
|
Herbst, A., Kordonouri, O., Schwab, K.O., Schmidt, F. and Holl, R.W. (2007) Impact of Physical Activity on Cardiovascular Risk Factors in Children with Type 1 Diabetes: A Multicenter Study of 23,251 Patients. Diabetes Care, 30, 2098-2100. https://doi.org/10.2337/dc06-2636
|
[14]
|
Miller, R.G., Mahajan, H.D., Costacou, T., Sekikawa, A., Anderson, S.J. and Orchard, T.J. (2016) A Contemporary Estimate of Total Mortality and Cardiovascular Disease Risk in Young Adults with Type 1 Diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care, 39, 2296-2303. https://doi.org/10.2337/dc16-1162
|
[15]
|
Kriska, A.M., LaPorte, R.E., Patrick, S.L., Kuller, L.H. and Orchard, T.J. (1991) The Association of Physical Activity and Diabetic Complications in Individuals with Insulin-Dependent Diabetes Mellitus: The Epidemiology of Diabetes Complications Study—VII. Journal of Clinical Epidemiology, 44, 1207-1214. https://doi.org/10.1016/0895-4356(91)90153-Z
|
[16]
|
Cryer, P.E. (1994) Hypoglycemia: The Limiting Factor in the Management of IDDM. Diabetes, 43, 1378-1389. https://doi.org/10.2337/diab.43.11.1378
|
[17]
|
Frid, A.H., Kreugel, G., Grassi, G., Halimi, S., Hicks, D., Hirsch, L.J., Smith, M.J., Wellhoener, R., Bode, B.W., Hirsch, I.B., et al. (2016) New Insulin Delivery Recommendations. Mayo Clinic Proceedings, 91, 1231-1255. https://doi.org/10.1016/j.mayocp.2016.06.010
|
[18]
|
Garg, S.K., Mathieu, C., Rais, N., Gao, H., Tobian, J.A., Gates, J.R., Ferguson, J.A., Webb, D.M. and Berclaz, P.Y. (2009) Two-Year Efficacy and Safety of AIR Inhaled Insulin in Patients with Type 1 Diabetes: An Open-Label Randomized Controlled Trial. Diabetes Technology & Therapeutics, 11, S5-S16. https://doi.org/10.1089/dia.2009.0040
|
[19]
|
Wolfsdorf, J.I., Glaser, N., Agus, M., Fritsch, M., Hanas, R., Rewers, A., Sperling, M.A. and Codner, E. (2018) ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic Ketoacidosis and the Hyperglycemic Hyperosmolar State. Pediatric Diabetes, 19, 155-177. https://doi.org/10.1111/pedi.12701
|
[20]
|
Jefferies, C., Rhodes, E., Rachmiel, M., Chizo, A.J., Kapellen, T., Abdulla, M.A. and Hofer, S.E. (2018) ISPAD Clinical Practice Consensus Guidelines 2018: Management of Children and Adolescents with Diabetes Requiring Surgery. Pediatric Diabetes, 19, 227-236. https://doi.org/10.1111/pedi.12733
|
[21]
|
Pérez, A., Ramos, A. and Carreras, G. (2020) Insulin Therapy in Hospitalized Patients. American Journal of Therapeutics, 27, e71-e78. https://doi.org/10.1097/MJT.0000000000001078
|
[22]
|
Rieger, C., Kurz, K., Mueller-Hoffmann, W., Gehr, B. and Liebl, A. (2019) New Design of a Percutaneous Port System for Continuous Intraperitoneal Insulin Infusion. Journal of Diabetes Science and Technology, 13, 1158-1160. https://doi.org/10.1177/1932296819855425
|
[23]
|
Spaan, N., Teplova, A., Stam, G., Spaan, J. and Lucas, C. (2014) Systematic Review: Continuous Intraperitoneal Insulin Infusion with Implantable Insulin Pumps for Diabetes Mellitus. Acta Diabetologica, 51, 339-351. https://doi.org/10.1007/s00592-014-0557-3
|
[24]
|
Karges, B., Boehm, B.O. and Karges, W. (2005) Early Hypoglycaemia after Accidental Intramuscular Injection of Insulin Glargine. Diabetic Medicine, 22, 1444-1445. https://doi.org/10.1111/j.1464-5491.2005.01654.x
|
[25]
|
Frid, A., Gunnarsson, R., Güntner, P. and Linde, B. (1988) Effects of Accidental Intramuscular Injection on Insulin Absorption in IDDM. Diabetes Care, 11, 41-45. https://doi.org/10.2337/diacare.11.1.41
|
[26]
|
Arbit, E. and Kidron, M. (2009) Oral Insulin: The Rationale for This Approach and Current Developments. Journal of Diabetes Science and Technology, 3, 562-567. https://doi.org/10.1177/193229680900300322
|
[27]
|
Krischer, J.P., Schatz, D.A., Bundy, B., Skyler, J.S. and Greenbaum, C.J. (2017) Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients with Type 1 Diabetes: A Randomized Clinical Trial. JAMA, 318, 1891-1902. https://doi.org/10.1001/jama.2017.17070
|
[28]
|
Kumar, V., Choudhry, I., Namdev, A., Mishra, S., Soni, S., Hurkat, P., Jain, A. and Jain, D. (2018) Oral Insulin: Myth or Reality. Current Diabetes Reviews, 14, 497-508. https://doi.org/10.2174/1573399813666170621122742
|
[29]
|
Sosenko, J.M., Skyler, J.S., Herold, K.C., Schatz, D.A., Haller, M.J., Pugliese, A., Cleves, M., Geyer, S., Rafkin, L.E., Matheson, D., et al. (2020) Slowed Metabolic Decline after 1 Year of Oral Insulin Treatment among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials. Diabetes, 69, 1827-1832. https://doi.org/10.2337/db20-0166
|
[30]
|
Assfalg, R., Knoop, J., Hoffman, K.L., Pfirrmann, M., Zapardiel-Gonzalo, J.M., Hofelich, A., Eugster, A., Weigelt, M., Matzke, C., Reinhardt, J., et al. (2021) Oral Insulin Immunotherapy in Children at Risk for Type 1 Diabetes in a Randomised Controlled Trial. Diabetologia, 64, 1079-1092. https://doi.org/10.1007/s00125-020-05376-1
|
[31]
|
Hirsch, I.B., Juneja, R., Beals, J.M., Antalis, C.J. and Wright, E.E. (2020) The Evolution of Insulin and How It Informs Therapy and Treatment Choices. Endocrine Reviews, 41, 733-755. https://doi.org/10.1210/endrev/bnaa015
|
[32]
|
Quianzon, C.C. and Cheikh, I. (2012) History of Insulin. Journal of Community Hospital Internal Medicine Perspectives, 2, Article ID: 18701. https://doi.org/10.3402/jchimp.v2i2.18701
|
[33]
|
Gottlieb, P.A. and Michels, A.W. (2020) Advances in Diabetes Treatment—Once-Weekly Insulin. The New England Journal of Medicine, 383, 2171-2172. https://doi.org/10.1056/NEJMe2031596
|
[34]
|
Markussen, J., Damgaard, U., Jørgensen, K.H., S
ørensen, E. and Thim, L. (1983) Human Monocomponent Insulin: Chemistry and Characteristics. Acta Medica Scandinavica, 213, 99-105. https://doi.org/10.1111/j.0954-6820.1983.tb08555.x
|
[35]
|
Galloway, J.A. (1980) Insulin Treatment for the Early 80s: Facts and Questions about Old and New Insulins and Their Usage. Diabetes Care, 3, 615-622. https://doi.org/10.2337/diacare.3.5.615
|
[36]
|
Tibaldi, J.M. (2014) Evolution of Insulin: From Human to Analog. The American Journal of Medicine, 127, S25-S38. https://doi.org/10.1016/j.amjmed.2014.07.005
|
[37]
|
American Diabetes Association (2020) Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43, S98-S110. https://doi.org/10.2337/dc20-S009
|
[38]
|
Danne, T., Phillip, M., Buckingham, B.A., Jarosz-Chobot, P., Saboo, B., Urakami, T., Battelino, T., Hanas, R. and Codner, E. (2018) ISPAD Clinical Practice Consensus Guidelines 2018: Insulin Treatment in Children and Adolescents with Diabetes. Pediatric Diabetes, 19, 115-135. https://doi.org/10.1111/pedi.12718
|
[39]
|
Holcombe, J.H., Zalani, S., Arora, V.K. and Mast, C.J. (2002) Comparison of Insulin Lispro with Regular Human Insulin for the Treatment of Type 1 Diabetes in Adolescents. Clinical Therapeutics, 24, 629-638. https://doi.org/10.1016/S0149-2918(02)85138-4
|
[40]
|
Deeb, L.C., Holcombe, J.H., Brunelle, R., Zalani, S., Brink, S., Jenner, M., Kitson, H., Perlman, K. and Spencer, M. (2001) Insulin Lispro Lowers Postprandial Glucose in Prepubertal Children with Diabetes. Pediatrics, 108, 1175-1179. https://doi.org/10.1542/peds.108.5.1175
|
[41]
|
Nicolucci, A., Ceriello, A., Di Bartolo, P., Corcos, A. and Orsini Federici, M. (2020) Rapid-Acting Insulin Analogues versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes. Diabetes Therapy, 11, 573-584. https://doi.org/10.1007/s13300-019-00732-w
|
[42]
|
Fullerton, B., Siebenhofer, A., Jeitler, K., Horvath, K., Semlitsch, T., Berghold, A., Plank, J., Pieber, T.R. and Gerlach, F.M. (2016) Short-Acting Insulin Analogues versus Regular Human Insulin for Adults with Type 1 Diabetes Mellitus. Cochrane Database of Systematic Reviews, 2016, CD012161. https://doi.org/10.1002/14651858.CD012161
|
[43]
|
Melo, K.F.S., Bahia, L.R., Pasinato, B., Porfirio, G.J.M., Martimbianco, A.L., Riera, R., Calliari, L.E.P., Minicucci, W.J., Turatti, L.A.A., Pedrosa, H.C., et al. (2019) Short-Acting Insulin Analogues versus Regular Human Insulin on Postprandial Glucose and Hypoglycemia in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetology & Metabolic Syndrome, 11, Article No. 2. https://doi.org/10.1186/s13098-018-0397-3
|
[44]
|
Lilly, E. (2019) US Prescribing Information—Humalog. https://pi.lilly.com/us/humalog-pen-pi.pdf
|
[45]
|
US Prescribing Information—Novolog. https://www.novo-pi.com/novolog.pdf
|
[46]
|
US Prescribing Information—Apidra. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021629s015lbl.pdf
|
[47]
|
Lindholm, A. and Jacobsen, L.V. (2001) Clinical Pharmacokinetics and Pharmacodynamics of Insulin Aspart. Clinical Pharmacokinetics, 40, 641-659. https://doi.org/10.2165/00003088-200140090-00002
|
[48]
|
Becker, R.H. and Frick, A.D. (2008) Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glulisine. Clinical Pharmacokinetics, 47, 7-20. https://doi.org/10.2165/00003088-200847010-00002
|
[49]
|
About Humalog® U-200 KwikPen®. https://www.humalog.com/u200
|
[50]
|
de la Peña, A., Seger, M., Soon, D., Scott, A.J., Reddy, S.R., Dobbins, M.A., Brown-Augsburger, P. and Linnebjerg, H. (2016) Bioequivalence and Comparative Pharmacodynamics of Insulin Lispro 200 U/mL Relative to Insulin Lispro (Humalog®) 100 U/mL. Clinical Pharmacology in Drug Development, 5, 69-75. https://doi.org/10.1002/cpdd.221
|
[51]
|
Heise, T., Nosek, L., Dellweg, S., Zijlstra, E., Præstmark, K.A., Kildegaard, J., Nielsen, G. and Sparre, T. (2014) Impact of Injection Speed and Volume on Perceived Pain during Subcutaneous Injections into the Abdomen and Thigh: A Single-Centre, Randomized Controlled Trial. Diabetes, Obesity & Metabolism, 16, 971-976. https://doi.org/10.1111/dom.12304
|
[52]
|
Hermansen, K., Fontaine, P., Kukolja, K.K., Peterkova, V., Leth, G. and Gall, M.A. (2004) Insulin Analogues (Insulin Detemir and Insulin Aspart) versus Traditional Human Insulins (NPH Insulin and Regular Human Insulin) in Basal-Bolus Therapy for Patients with Type 1 Diabetes. Diabetologia, 47, 622-629. https://doi.org/10.1007/s00125-004-1365-z
|
[53]
|
Monami, M., Marchionni, N. and Mannucci, E. (2009) Long-Acting Insulin Analogues vs. NPH Human Insulin in Type 1 Diabetes. A Meta-Analysis. Diabetes, Obesity & Metabolism, 11, 372-378. https://doi.org/10.1111/j.1463-1326.2008.00976.x
|
[54]
|
Chase, H.P., Dixon, B., Pearson, J., Fiallo-Scharer, R., Walravens, P., Klingensmith, G., Rewers, M. and Garg, S.K. (2003) Reduced Hypoglycemic Episodes and Improved Glycemic Control in Children with Type 1 Diabetes Using Insulin Glargine and Neutral Protamine Hagedorn Insulin. The Journal of Pediatrics, 143, 737-740. https://doi.org/10.1067/S0022-3476(03)00415-3
|
[55]
|
Heinemann, L., Linkeschova, R., Rave, K., Hompesch, B., Sedlak, M. and Heise, T. (2000) Time-Action Profile of the Long-Acting Insulin analog Insulin Glargine (HOE901) in Comparison with Those of NPH Insulin and Placebo. Diabetes Care, 23, 644-649. https://doi.org/10.2337/diacare.23.5.644
|
[56]
|
Becker, R.H., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T. and Heise, T. (2015) New Insulin Glargine 300 Units∙mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared with Insulin Glargine 100 Units∙mL−1. Diabetes Care, 38, 637-643. https://doi.org/10.2337/dc14-0006
|
[57]
|
Pearson, S.M. and Trujillo, J.M. (2018) Conversion from Insulin Glargine U-100 to Insulin Glargine U-300 or Insulin Degludec and the Impact on Dosage Requirements. Therapeutic Advances in Endocrinology and Metabolism, 9, 113-121. https://doi.org/10.1177/2042018818760962
|
[58]
|
Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J. and Kurtzhals, P. (2004) The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin. Pharmaceutical Research, 21, 1498-1504. https://doi.org/10.1023/B:PHAM.0000036926.54824.37
|
[59]
|
Klein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L. and Heise, T. (2007) Albumin-Bound Basal Insulin Analogues (Insulin Detemir and NN344): Comparable Time-Action Profiles but Less Variability than Insulin Glargine in Type 2 Diabetes. Diabetes, Obesity & Metabolism, 9, 290-299. https://doi.org/10.1111/j.1463-1326.2006.00685.x
|
[60]
|
Degludec Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203314lbl.pdf
|
[61]
|
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D.B., Wahlund, P.O. and Ribel, U. (2012) Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-Long-Acting Basal Insulin. Pharmaceutical Research, 29, 2104-2114. https://doi.org/10.1007/s11095-012-0739-z
|
[62]
|
Lane, W., Bailey, T.S., Gerety, G., Gumprecht, J., Philis-Tsimikas, A., Hansen, C.T., Nielsen, T.S.S., and Warren, M. (2017) Effect of Insulin Degludec vs. Insulin Glargine U100 on Hypoglycemia in Patients with Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA, 318, 33-44. https://doi.org/10.1001/jama.2017.7115
|
[63]
|
Holmes, R.S., Crabtree, E. and McDonagh, M.S. (2019) Comparative Effectiveness and Harms of Long-Acting Insulins for Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes, Obesity & Metabolism, 21, 984-992. https://doi.org/10.1111/dom.13614
|
[64]
|
Thalange, N., Deeb, L., Iotova, V., Kawamura, T., Klingensmith, G., Philotheou, A., Silverstein, J., Tumini, S., Ocampo Francisco, A.M., Kinduryte, O., et al. (2015) Insulin Degludec in Combination with Bolus Insulin Aspart Is Safe and Effective in Children and Adolescents with Type 1 Diabetes. Pediatric Diabetes, 16, 164-176. https://doi.org/10.1111/pedi.12263
|
[65]
|
Korsatko, S., Deller, S., Koehler, G., Mader, J.K., Neubauer, K., Adrian, C.L., Thomsen, H., Haahr, H. and Pieber, T.R. (2013) A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec. Clinical Drug Investigation, 33, 515-521. https://doi.org/10.1007/s40261-013-0096-7
|
[66]
|
Cobry, E., McFann, K., Messer, L., Gage, V., VanderWel, B., Horton, L. and Chase, H.P. (2010) Timing of Meal Insulin Boluses to Achieve Optimal Postprandial Glycemic Control in Patients with Type 1 Diabetes. Diabetes Technology & Therapeutics, 12, 173-177. https://doi.org/10.1089/dia.2009.0112
|
[67]
|
Evans, M., Ceriello, A., Danne, T., De Block, C., DeVries, J.H., Lind, M., Mathieu, C., Nørgaard, K., Renard, E. and Wilmot, E.G. (2019) Use of Fast-Acting Insulin Aspart in Insulin Pump Therapy in Clinical Practice. Diabetes, Obesity & Metabolism, 21, 2039-2047. https://doi.org/10.1111/dom.13798
|
[68]
|
Bode, B.W., Iotova, V., Kovarenko, M., Laffel, L.M., Rao, P.V., Deenadayalan, S., Ekelund, M., Larsen, S.F. and Danne, T. (2019) Efficacy and Safety of Fast-Acting Insulin Aspart Compared with Insulin Aspart, Both in Combination with Insulin Degludec, in Children and Adolescents with Type 1 Diabetes: The Onset 7 Trial. Diabetes Care, 42, 1255-1262. https://doi.org/10.2337/dc19-0009
|
[69]
|
Fiasp Announcement. https://www.ajmc.com/view/fda-approves-fiasp-for-children-with-diabetes
|
[70]
|
Linnebjerg, H., Zhang, Q., LaBell, E., Dellva, M.A., Coutant, D.E., Hövelmann, U., Plum-Mörschel, L., Herbrand, T. and Leohr, J. (2020) Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial. Clinical Pharmacokinetics, 59, 1589-1599. https://doi.org/10.1007/s40262-020-00903-0
|
[71]
|
Ultra Rapid Lispro Approval. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lyumjevtm-insulin-lispro-aabc-injection-lillys-new
|
[72]
|
Bode, B.W., Garg, S.K., Norwood, P., Morales, C., Hardy, T., Liu, R. and Ignaut, D. (2021) Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study. Diabetes Technology & Therapeutics, 23, 41-50. https://doi.org/10.1089/dia.2020.0224
|
[73]
|
Lasalvia, P., Barahona-Correa, J.E., Romero-Alvernia, D.M., Gil-Tamayo, S., Castañeda-Cardona, C., Bayona, J.G., Triana, J.J., Laserna, A.F., Mejía-Torres, M., Restrepo-Jimenez, P., et al. (2016) Pen Devices for Insulin Self-Administration Compared with Needle and Vial: Systematic Review of the Literature and Meta-Analysis. Journal of Diabetes Science and Technology, 10, 959-966. https://doi.org/10.1177/1932296816633721
|
[74]
|
Ignaut, D.A. and Venekamp, W.J. (2007) HumaPen Memoir: A Novel Insulin-Injecting Pen with a Dose-Memory Feature. Expert Review of Medical Devices, 4, 793-802. https://doi.org/10.1586/17434440.4.6.793
|
[75]
|
Medical, C. (2021) InPen User Guide. https://www.companionmedical.com/guides/inpen-user-guide.pdf
|
[76]
|
Kampmann, U., Madsen, L.R., Bjerg, L., Witte, D.R., Hasselstrøm, K., Østergård, T., Alstrup, K., Møller, M.K., Dylmer, D. and Hansen, K.W. (2018) Prevalence and Geographical Distribution of Insulin Pump Therapy in the Central Denmark Region and Its Association with Metabolic Parameters. Diabetes Research and Clinical Practice, 141, 148-155. https://doi.org/10.1016/j.diabres.2018.04.042
|
[77]
|
Gajewska, K.A., Bennett, K., Biesma, R. and Sreenan, S. (2020) Low Uptake of Continuous Subcutaneous Insulin Infusion Therapy in People with Type 1 Diabetes in Ireland: A Retrospective Cross-Sectional Study. BMC Endocrine Disorders, 20, Article No. 92. https://doi.org/10.1186/s12902-020-00573-w
|
[78]
|
Foster, N.C., Beck, R.W., Miller, K.M., Clements, M.A., Rickels, M.R., DiMeglio, L.A., Maahs, D.M., Tamborlane, W.V., Bergenstal, R., Smith, E., et al. (2019) State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technology & Therapeutics, 21, 66-72. https://doi.org/10.1089/dia.2018.0384
|
[79]
|
Sora, N.D., Shashpal, F., Bond, E.A. and Jenkins, A.J. (2019) Insulin Pumps: Review of Technological Advancement in Diabetes Management. The American Journal of the Medical Sciences, 358, 326-331. https://doi.org/10.1016/j.amjms.2019.08.008
|
[80]
|
Alsaleh, F.M., Smith, F.J., Keady, S. and Taylor, K.M. (2010) Insulin Pumps: From Inception to the Present and toward the Future. Journal of Clinical Pharmacy and Therapeutics, 35, 127-138. https://doi.org/10.1111/j.1365-2710.2009.01048.x
|
[81]
|
Shashaj, B., Busetto, E. and Sulli, N. (2008) Benefits of a Bolus Calculator in Pre- and Postprandial Glycaemic Control and Meal Flexibility of Paediatric Patients Using Continuous Subcutaneous Insulin Infusion (CSII). Diabetic Medicine, 25, 1036-1042. https://doi.org/10.1111/j.1464-5491.2008.02549.x
|
[82]
|
Zisser, H., Wagner, R., Pleus, S., Haug, C., Jendrike, N., Parkin, C., Schweitzer, M. and Freckmann, G. (2010) Clinical Performance of Three Bolus Calculators in Subjects with Type 1 Diabetes Mellitus: A Head-to-Head-to-Head Comparison. Diabetes Technology & Therapeutics, 12, 955-961. https://doi.org/10.1089/dia.2010.0064
|
[83]
|
Tandem. Control IQ User Guide. https://www.tandemdiabetes.com/docs/default-source/product-documents/t-slim-x2-insulin-pump/aw-1005628_c_user-guide-tslim-x2-control-iq-7-4-mgdl-artwork.pdf?sfvrsn=18a507d7_140
|
[84]
|
Medtronic. MiniMed™ 670G System. https://www.medtronicdiabetes.com/download-library/minimed-670g-system
|
[85]
|
OmniPod User Guide. https://www.omnipod.com/sites/default/files/2021-04/Omnipod-DASH_User-Guide_English.pdf
|
[86]
|
Medtronic MiniMed™ 640G System User Guide. https://hcp.medtronic-diabetes.com.au/sites/default/files/minimed-640g-system-user-guide-mmol.pdf
|
[87]
|
Siebenhofer, A., Jeitler, K., Berghold, A., Horvath, K. and Pieber, T.R. (2009) Severe Hypoglycaemia and Glycaemic Control in Type 1 Diabetes: Meta-Analysis of Multiple Daily Insulin Injections Compared with Continuous Subcutaneous Insulin Infusion. Diabetic Medicine, 26, 311-312; author reply 312-313. https://doi.org/10.1111/j.1464-5491.2009.02668.x
|
[88]
|
Haynes, E., Ley, M., Talbot, P., Dunbar, M. and Cummings, E. (2021) Insulin Pump Therapy Improves Quality of Life of Young Patients with Type 1 Diabetes Enrolled in a Government-Funded Insulin Pump Program: A Qualitative Study. The Canadian Journal of Diabetes, 45, 395-402. https://doi.org/10.1016/j.jcjd.2020.08.101
|
[89]
|
Al Shaikh, A., Al Zahrani, A.M., Qari, Y.H., AbuAlnasr, A.A., Alhawsawi, W.K., Alshehri, K.A. and AlShaikh, S.A. (2020) Quality of Life in Children with Diabetes Treated with Insulin Pump Compared with Multiple Daily Injections in Tertiary Care Center. Clinical Medicine Insights: Endocrinology and Diabetes, 13. https://doi.org/10.1177/1179551420959077
|
[90]
|
Heller, S., White, D., Lee, E., Lawton, J., Pollard, D., Waugh, N., Amiel, S., Barnard, K., Beckwith, A., Brennan, A., et al. (2017) A Cluster Randomised Trial, Cost-Effectiveness Analysis and Psychosocial Evaluation of Insulin Pump Therapy Compared with Multiple Injections during Flexible Intensive Insulin Therapy for Type 1 Diabetes: The REPOSE Trial. Health Technology Assessment (Winchester, England), 21. https://doi.org/10.3310/hta21200
|
[91]
|
Pańkowska, E., Szypowska, A., Lipka, M., Szpotańska, M., Błazik, M. and Groele, L. (2009) Application of Novel Dual Wave Meal Bolus and Its Impact on Glycated Hemoglobin A1c Level in Children with Type 1 Diabetes. Pediatric Diabetes, 10, 298-303. https://doi.org/10.1111/j.1399-5448.2008.00471.x
|
[92]
|
Dos Santos, T.J., Donado Campos, J.M., Argente, J. and Rodríguez-Artalejo, F. (2021) Effectiveness and Equity of Continuous Subcutaneous Insulin Infusions in Pediatric Type 1 Diabetes: A Systematic Review and Meta-Analysis of the Literature. Diabetes Research and Clinical Practice, 172, Article ID: 108643. https://doi.org/10.1016/j.diabres.2020.108643
|
[93]
|
Monami, M., Lamanna, C., Marchionni, N. and Mannucci, E. (2010) Continuous Subcutaneous Insulin Infusion versus Multiple Daily Insulin Injections in Type 1 Diabetes: A Meta-Analysis. Acta Diabetologica, 47, 77-81. https://doi.org/10.1007/s00592-009-0132-5
|
[94]
|
Zhang, Y., Li, S., Zou, Y., Wu, X., Bi, Y., Zhang, L., Yuan, Y., Gong, W. and Hayter, M. (2021) Fear of Hypoglycemia in Patients with Type 1 and 2 Diabetes: A Systematic Review. Journal of Clinical Nursing, 30, 72-82. https://doi.org/10.1111/jocn.15538
|
[95]
|
Barnard, K., Thomas, S., Royle, P., Noyes, K. and Waugh, N. (2010) Fear of Hypoglycaemia in Parents of Young Children with Type 1 Diabetes: A Systematic Review. BMC Pediatrics, 10, Article No. 50. https://doi.org/10.1186/1471-2431-10-50
|
[96]
|
Schmidt, S., Andersen Nexø, M., Norgaard, O., Willaing, I., Pedersen-Bjergaard, U., Skinner, T.C. and Nørgaard, K. (2020) Psychosocial Factors Associated with HbA1c in Adults with Insulin Pump-Treated Type 1 Diabetes: A Systematic Review. Diabetic Medicine, 37, 1454-1462. https://doi.org/10.1111/dme.14347
|
[97]
|
MiniMed® Veo™ Paradigm™ System. https://www.medtronic-diabetes.com.au/sites/default/files/veo-step-by-step-guide-fa3-view.pdf
|
[98]
|
Agrawal, P., Welsh, J.B., Kannard, B., Askari, S., Yang, Q. and Kaufman, F.R. (2011) Usage and Effectiveness of the Low Glucose Suspend Feature of the Medtronic Paradigm Veo Insulin Pump. Journal of Diabetes Science and Technology, 5, 1137-1141. https://doi.org/10.1177/193229681100500514
|
[99]
|
Choudhary, P., Shin, J., Wang, Y., Evans, M.L., Hammond, P.J., Kerr, D., Shaw, J.A., Pickup, J.C. and Amiel, S.A. (2011) Insulin Pump Therapy with Automated Insulin Suspension in Response to Hypoglycemia: Reduction in Nocturnal Hypoglycemia in Those at Greatest Risk. Diabetes Care, 34, 2023-2025. https://doi.org/10.2337/dc10-2411
|
[100]
|
Basal IQ User Guide. https://www.tandemdiabetes.com/docs/default-source/product-documents/t-slim-x2-insulin-pump/aw-1006684_c-user-guide-tslim-x2-basal-iq-6-4-mmoll-artwork-web.pdf?sfvrsn=eeb230d7_139
|
[101]
|
Medtronic MiniMed™ 640G System User Guide. https://hcp.medtronic-diabetes.com.au/sites/default/files/minimed-640g-system-user-guide-mmol.pdf
|
[102]
|
Beato-Víbora, P.I., Gil-Poch, E., Galán-Bueno, L., Lázaro-Martín, L. and Arroyo-Díez, F.J. (2018) The Incremental Benefits of the Predictive Low-Glucose Suspend Function Compared to the Low-Glucose Suspend Function as Automation Against Hypoglycemia in Sensor-Augmented Pump Therapy. Journal of Diabetes Science and Technology, 12, 1241-1243. https://doi.org/10.1177/1932296818791536
|
[103]
|
Kovatchev, B. (2018) Automated Closed-Loop Control of Diabetes: The Artificial Pancreas. Bioelectronic Medicine, 4, Article No. 14. https://doi.org/10.1186/s42234-018-0015-6
|
[104]
|
Medtronic. MiniMed™ 770G System. https://www.medtronicdiabetes.com/download-library/minimed-770g-system
|
[105]
|
Garg, S.K., Weinzimer, S.A., Tamborlane, W.V., Buckingham, B.A., Bode, B.W., Bailey, T.S., Brazg, R.L., Ilany, J., Slover, R.H., Anderson, S.M., et al. (2017) Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics, 19, 155-163. https://doi.org/10.1089/dia.2016.0421
|
[106]
|
Forlenza, G.P., Pinhas-Hamiel, O., Liljenquist, D.R., Shulman, D.I., Bailey, T.S., Bode, B.W., Wood, M.A., Buckingham, B.A., Kaiserman, K.B., Shin, J., et al. (2019) Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes. Diabetes Technology & Therapeutics, 21, 11-19. https://doi.org/10.1089/dia.2018.0264
|
[107]
|
Collyns, O.J., Meier, R.A., Betts, Z.L., Chan, D.S.H., Frampton, C., Frewen, C.M., Hewapathirana, N.M., Jones, S.D., Roy, A., Grosman, B., et al. (2021) Improved Glycemic Outcomes with Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results from a Randomized Crossover Trial Comparing Automated Insulin Delivery with Predictive Low Glucose Suspend in People with Type 1 Diabetes. Diabetes Care, 44, 969-975. https://doi.org/10.2337/figshare.13618910.v1
|
[108]
|
Bergenstal, R.M., Nimri, R., Beck, R.W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S.A., Sibayan, J., et al. (2021) A Comparison of Two Hybrid Closed-Loop Systems in Adolescents and Young Adults with Type 1 Diabetes (FLAIR): A Multicentre, Randomised, Crossover Trial. The Lancet, 397, 208-219. https://doi.org/10.1016/S0140-6736(20)32514-9
|
[109]
|
Messer, L.H., Berget, C., Vigers, T., Pyle, L., Geno, C., Wadwa, R.P., Driscoll, K.A. and Forlenza, G.P. (2020) Real World Hybrid Closed-Loop Discontinuation: Predictors and Perceptions of Youth Discontinuing the 670G System in the First 6 Months. Pediatric Diabetes, 21, 319-327. https://doi.org/10.1111/pedi.12971
|
[110]
|
Lal, R.A., Basina, M., Maahs, D.M., Hood, K., Buckingham, B. and Wilson, D.M. (2019) One Year Clinical Experience of the First Commercial Hybrid Closed-Loop. Diabetes Care, 42, 2190-2196. https://doi.org/10.2337/dc19-0855
|
[111]
|
Brown, S.A., Kovatchev, B.P., Raghinaru, D., Lum, J.W., Buckingham, B.A., Kudva, Y.C., Laffel, L.M., Levy, C.J., Pinsker, J.E., Wadwa, R.P., et al. (2019) Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. The New England Journal of Medicine, 381, 1707-1717. https://doi.org/10.1056/NEJMoa1907863
|
[112]
|
Breton, M.D., Kanapka, L.G., Beck, R.W., Ekhlaspour, L., Forlenza, G.P., Cengiz, E., Schoelwer, M., Ruedy, K.J., Jost, E., Carria, L., et al. (2020) A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. The New England Journal of Medicine, 383, 836-845. https://doi.org/10.1056/NEJMoa2004736
|
[113]
|
Breton, M.D. and Kovatchev, B.P. (2021) One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technology & Therapeutics, 23, 601-608. https://doi.org/10.1089/dia.2021.0097
|
[114]
|
Brown, S.A., Forlenza, G.P., Bode, B.W., Pinsker, J.E., Levy, C.J., Criego, A.B., Hansen, D.W., Hirsch, I.B., Carlson, A.L., Bergenstal, R.M., et al. (2021) Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System with Customizable Glycemic Targets in Pediatric and Adult Participants with Type 1 Diabetes. Diabetes Care, 44, 1630-1640. https://doi.org/10.2337/dc21-0172
|
[115]
|
Sherr, J.L., Buckingham, B.A., Forlenza, G.P., Galderisi, A., Ekhlaspour, L., Wadwa, R.P., Carria, L., Hsu, L., Berget, C., Peyser, T.A., et al. (2020) Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes over 5 Days under Free-Living Conditions. Diabetes Technology & Therapeutics, 22, 174-184. https://doi.org/10.1089/dia.2019.0286
|
[116]
|
Buckingham, B.A., Forlenza, G.P., Pinsker, J.E., Christiansen, M.P., Wadwa, R.P., Schneider, J., Peyser, T.A., Dassau, E., Lee, J.B., O’Connor, J., et al. (2018) Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes Technology & Therapeutics, 20, 257-262. https://doi.org/10.1089/dia.2017.0346
|
[117]
|
CamAPS FX User Manual. https://s3-eu-west-1.amazonaws.com/camdiab.user.manual/user_manual_fx_mmoll_commercial.pdf
|
[118]
|
Leelarathna, L., Choudhary, P., Wilmot, E.G., Lumb, A., Street, T., Kar, P. and Ng, S.M. (2021) Hybrid Closed-Loop Therapy: Where Are We in 2021? Diabetes, Obesity & Metabolism, 23, 655-660. https://doi.org/10.1111/dom.14273
|
[119]
|
Chen, N.S., Boughton, C.K., Hartnell, S., Fuchs, J., Allen, J.M., Willinska, M.E., Thankamony, A., de Beaufort, C., Campbell, F.M., Fröhlich-Reiterer, E., et al. (2021) User Engagement with the CamAPS FX Hybrid Closed-Loop App According to Age and User Characteristics. Diabetes Care, 44, e148-e150. https://doi.org/10.2337/dc20-2762
|
[120]
|
Thabit, H., Tauschmann, M., Allen, J.M., Leelarathna, L., Hartnell, S., Wilinska, M.E., Acerini, C.L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) Home Use of an Artificial Beta Cell in Type 1 Diabetes. The New England Journal of Medicine, 373, 2129-2140. https://doi.org/10.1056/NEJMoa1509351
|
[121]
|
Amadou, C., Franc, S., Benhamou, P.Y., Lablanche, S., Huneker, E., Charpentier, G. and Penfornis, A. (2021) Diabeloop DBLG1 Closed-Loop System Enables Patients with Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations without Serious Adverse Events: 6-Month Follow-Up. Diabetes Care, 44, 844-846. https://doi.org/10.2337/dc20-1809
|
[122]
|
Benhamou, P.Y., Huneker, E., Franc, S., Doron, M. and Charpentier, G. (2018) Customization of Home Closed-Loop Insulin Delivery in Adult Patients with Type 1 Diabetes, Assisted with Structured Remote Monitoring: The Pilot WP7 Diabeloop Study. Acta Diabetologica, 55, 549-556. https://doi.org/10.1007/s00592-018-1123-1
|
[123]
|
Viñals, C., Beneyto, A., Martín-SanJosé, J.F., Furió-Novejarque, C., Bertachi, A., Bondia, J., Vehi, J., Conget, I. and Giménez, M. (2021) Artificial Pancreas with Carbohydrate Suggestion Performance for Unannounced and Announced Exercise in Type 1 Diabetes. The Journal of Clinical Endocrinology and Metabolism, 106, 55-63. https://doi.org/10.1210/clinem/dgaa562
|
[124]
|
Omer, T. (2016) Empowered Citizen “Health Hackers” Who Are Not Waiting. BMC Medicine, 14, Article No. 118. https://doi.org/10.1186/s12916-016-0670-y
|
[125]
|
Loop and Learn—FreeAPS. https://www.loopnlearn.org/freeapsdoc/
|
[126]
|
Kesavadev, J., Srinivasan, S., Saboo, B., Krishna, B.M. and Krishnan, G. (2020) The Do-It-Yourself Artificial Pancreas: A Comprehensive Review. Diabetes Therapy, 11, 1217-1235. https://doi.org/10.1007/s13300-020-00823-z
|
[127]
|
OpenAPS Outcomes. https://openaps.org/outcomes/
|
[128]
|
Lum, J. (2020) Loop Observational Study—Evaluating Do-It-Yourself (DIY) Automated Insulin Delivery. ATTD 2020, Madrid.
|
[129]
|
Tidepool iAC. https://www.tidepool.org/blog/interoperability-is-the-how-not-the-why
|
[130]
|
Toffanin, C., Kozak, M., Sumnik, Z., Cobelli, C. and Petruzelkova, L. (2020) In Silico Trials of an Open-Source Android-Based Artificial Pancreas: A New Paradigm to Test Safety and Efficacy of Do-It-Yourself Systems. Diabetes Technology & Therapeutics, 22, 112-120. https://doi.org/10.1089/dia.2019.0375
|
[131]
|
Jennings, P. and Hussain, S. (2020) Do-It-Yourself Artificial Pancreas Systems: A Review of the Emerging Evidence and Insights for Healthcare Professionals. Journal of Diabetes Science and Technology, 14, 868-877. https://doi.org/10.1177/1932296819894296
|
[132]
|
Mack, G.S. (2007) Pfizer Dumps Exubera. Nature Biotechnology, 25, 1331-1332. https://doi.org/10.1038/nbt1207-1331
|
[133]
|
Afrezza Prescribing Information. https://www.afrezza.com/pdf/Full-Prescribing-Information.pdf
|
[134]
|
Gerber, R.A., Cappelleri, J.C., Kourides, I.A. and Gelfand, R.A. (2001) Treatment Satisfaction with Inhaled Insulin in Patients with Type 1 Diabetes: A Randomized Controlled Trial. Diabetes Care, 24, 1556-1559. https://doi.org/10.2337/diacare.24.9.1556
|
[135]
|
Royle, P., Waugh, N., McAuley, L., McIntyre, L. and Thomas, S. (2003) Inhaled Insulin in Diabetes Mellitus. Cochrane Database of Systematic Reviews, 2003, CD003890. https://doi.org/10.1002/14651858.CD003890.pub2
|
[136]
|
Pittas, A.G., Westcott, G.P. and Balk, E.M. (2015) Efficacy, Safety, and Patient Acceptability of Technosphere Inhaled Insulin for People with Diabetes: A Systematic Review and Meta-Analysis. The Lancet Diabetes & Endocrinology, 3, 886-894. https://doi.org/10.1016/S2213-8587(15)00280-6
|
[137]
|
Galderisi, A., Cohen, N., Calhoun, P., Kraemer, K., Breton, M., Weinzimer, S. and Cengiz, E. (2020) Effect of Afrezza on Glucose Dynamics during HCL Treatment. Diabetes Care, 43, 2146-2152. https://doi.org/10.2337/dc20-0091
|
[138]
|
Santos, L.L., Lima, F.J.C., Sousa-Rodrigues, C.F. and Barbosa, F.T. (2017) Use of SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. Revista da Associacao Medica Brasileira, 63, 636-641. https://doi.org/10.1590/1806-9282.63.07.636
|
[139]
|
Buse, J.B., Garg, S.K., Rosenstock, J., Bailey, T.S., Banks, P., Bode, B.W., Danne, T., Kushner, J.A., Lane, W.S., Lapuerta, P., et al. (2018) Sotagliflozin in Combination with Optimized Insulin Therapy in Adults with Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care, 41, 1970-1980. https://doi.org/10.2337/dc18-0343
|
[140]
|
Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschope, D., Thoren, F., Xu, J. and Langkilde, A.M. (2018) Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care, 41, 2552-2559. https://doi.org/10.2337/dc18-1087
|
[141]
|
Rosenstock, J., Marquard, J., Laffel, L.M., Neubacher, D., Kaspers, S., Cherney, D.Z., Zinman, B., Skyler, J.S., George, J., Soleymanlou, N., et al. (2018) Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care, 41, 2560-2569. https://doi.org/10.2337/dc18-1749
|
[142]
|
Yu, X., Zhang, S. and Zhang, L. (2018) Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis. International Journal of Endocrinology, 2018, Article ID: 7074868. https://doi.org/10.1155/2018/7074868
|
[143]
|
Lu, J., Tang, L., Meng, H., Zhao, J. and Liang, Y. (2019) Effects of Sodium-Glucose Cotransporter (SGLT) Inhibitors in Addition to Insulin Therapy on Glucose Control and Safety Outcomes in Adults with Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Diabetes/Metabolism Research and Reviews, 35, e3169. https://doi.org/10.1002/dmrr.3169
|
[144]
|
Teymourian, H., Moonla, C., Tehrani, F., Vargas, E., Aghavali, R., Barfidokht, A., Tangkuaram, T., Mercier, P.P., Dassau, E. and Wang, J. (2020) Microneedle-Based Detection of Ketone Bodies along with Glucose and Lactate: Toward Real-Time Continuous Interstitial Fluid Monitoring of Diabetic Ketosis and Ketoacidosis. Analytical Chemistry, 92, 2291-2300. https://doi.org/10.1021/acs.analchem.9b05109
|
[145]
|
Flores, M., Amir, M., Ahmed, R., Alashi, S., Li, M., Wang, X., Lansang, M.C. and Al-Jaghbeer, M.J. (2020) Causes of Diabetic Ketoacidosis among Adults with Type 1 Diabetes Mellitus: Insulin Pump Users and Non-Users. BMJ Open Diabetes & Research Care, 8, e001329.
|
[146]
|
Miller, E., Doshi, A., Grøn, R., Jódar, E., Őrsy, P., Ranthe, M.F., Sugimoto, D., Tentolouris, N., Viljoen, A. and Billings, L.K. (2019) IDegLira Improves Patient-Reported Outcomes While Using a Simple Regimen with Fewer Injections and Dose Adjustments Compared with Basal-Bolus Therapy. Diabetes, Obesity & Metabolism, 21, 2643-2650. https://doi.org/10.1111/dom.13851
|
[147]
|
Rosenstock, J., Bajaj, H.S., Janež, A., Silver, R., Begtrup, K., Hansen, M.V., Jia, T. and Goldenberg, R. (2020) Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. The New England Journal of Medicine, 383, 2107-2116. https://doi.org/10.1056/NEJMoa2022474
|
[148]
|
Ozer, K., Cooper, A.M., Ahn, L.P., Waggonner, C.R. and Blevins, T.C. (2021) Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study. Diabetes Technology & Therapeutics, 23, 286-292. https://doi.org/10.1089/dia.2020.0500
|
[149]
|
Grosman, B., Wu, D., Parikh, N., Roy, A., Voskanyan, G., Kurtz, N., Sturis, J., Cohen, O., Ekelund, M. and Vigersky, R. (2021) Fast-Acting Insulin Aspart (Fiasp®) Improves Glycemic Outcomes When Used with MiniMed(TM) 670G Hybrid Closed-Loop System in Simulated Trials Compared to NovoLog®. Computer Methods and Programs in Biomedicine, 205, Article ID: 106087. https://doi.org/10.1016/j.cmpb.2021.106087
|
[150]
|
Hsu, L., Buckingham, B., Basina, M., Ekhlaspour, L., von Eyben, R., Wang, J. and Lal, R.A. (2021) Fast-Acting Insulin Aspart Use with the MiniMed™ 670G System. Diabetes Technology & Therapeutics, 23, 1-7. https://doi.org/10.1089/dia.2020.0083
|
[151]
|
Boughton, C.K., Hartnell, S., Thabit, H., Poettler, T., Herzig, D., Wilinska, M.E., Ashcroft, N.L., Sibayan, J., Cohen, N., Calhoun, P., Bally, L., et al. (2021) Hybrid Closed-Loop Glucose Control with Faster Insulin Aspart Compared with Standard Insulin Aspart in Adults with Type 1 Diabetes: A Double-Blind, Multicentre, Multinational, Randomized, Crossover Study. Diabetes, Obesity & Metabolism, 23, 1389-1396. https://doi.org/10.1111/dom.14355
|
[152]
|
Tsoukas, M.A., Cohen, E., Legault, L., von Oettingen, J.E., Yale, J.F., Vallis, M., Odabassian, M., El Fathi, A., Rutkowski, J., Jafar, A., et al. (2021) Alleviating Carbohydrate Counting with a FiASP-plus-Pramlintide Closed-Loop Delivery System (Artificial Pancreas): Feasibility and Pilot Studies. Diabetes, Obesity & Metabolism, 23, 2090-2098. https://doi.org/10.1111/dom.14447
|
[153]
|
OpenAPS. https://openaps.readthedocs.io/en/latest/docs/Customize-Iterate/oref1.html#understanding-unannounced-meals-uam
|
[154]
|
Pohl, R., Li, M., Krasner, A. and De Souza, E. (2015) Development of Stable Liquid Glucagon Formulations for Use in Artificial Pancreas. Journal of Diabetes Science and Technology, 9, 8-16. https://doi.org/10.1177/1932296814555541
|
[155]
|
Castle, J.R., Youssef, J.E., Branigan, D., Newswanger, B., Strange, P., Cummins, M., Shi, L. and Prestrelski, S. (2016) Comparative Pharmacokinetic/Pharmacodynamic Study of Liquid Stable Glucagon versus Lyophilized Glucagon in Type 1 Diabetes Subjects. Journal of Diabetes Science and Technology, 10, 1101-1107. https://doi.org/10.1177/1932296816653141
|
[156]
|
Blair, H.A. (2021) Dasiglucagon: First Approval. Drugs, 81, 1115-1120. https://doi.org/10.1007/s40265-021-01531-z
|
[157]
|
Taleb, N., Emami, A., Suppere, C., Messier, V., Legault, L., Ladouceur, M., Chiasson, J.L., Haidar, A. and Rabasa-Lhoret, R. (2016) Efficacy of Single-Hormone and Dual-Hormone Artificial Pancreas during Continuous and Interval Exercise in Adult Patients with Type 1 Diabetes: Randomised Controlled Crossover Trial. Diabetologia, 59, 2561-2571. https://doi.org/10.1007/s00125-016-4107-0
|
[158]
|
Castle, J.R., El Youssef, J., Wilson, L.M., Reddy, R., Resalat, N., Branigan, D., Ramsey, K., Leitschuh, J., Rajhbeharrysingh, U., Senf, B., et al. (2018) Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors. Diabetes Care, 41, 1471-1477. https://doi.org/10.2337/dc18-0228
|
[159]
|
Haidar, A., Legault, L., Messier, V., Mitre, T.M., Leroux, C. and Rabasa-Lhoret, R. (2015) Comparison of Dual-Hormone Artificial Pancreas, Single-Hormone Artificial Pancreas, and Conventional Insulin Pump Therapy for Glycaemic Control in Patients with Type 1 Diabetes: An Open-Label Randomised Controlled Crossover Trial. The Lancet Diabetes & Endocrinology, 3, 17-26. https://doi.org/10.1016/S2213-8587(14)70226-8
|
[160]
|
Russell, S.J., Hillard, M.A., Balliro, C., Magyar, K.L., Selagamsetty, R., Sinha, M., Grennan, K., Mondesir, D., Ekhlaspour, L., Zheng, H., et al. (2016) Day and Night Glycaemic Control with a Bionic Pancreas versus Conventional Insulin Pump Therapy in Preadolescent Children with Type 1 Diabetes: A Randomised Crossover Trial. The Lancet Diabetes & Endocrinology, 4, 233-243. https://doi.org/10.1016/S2213-8587(15)00489-1
|
[161]
|
Castellanos, L.E., Balliro, C.A., Sherwood, J.S., Jafri, R., Hillard, M.A., Greaux, E., Selagamsetty, R., Zheng, H., El-Khatib, F.H., Damiano, E.R., et al. (2021) Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults with Type 1 Diabetes in a Home-Use Setting. Diabetes Care, 44, e118-e120. https://doi.org/10.2337/dc20-1086
|
[162]
|
Wilson, L.M., Jacobs, P.G., Ramsey, K.L., Resalat, N., Reddy, R., Branigan, D., Leitschuh, J., Gabo, V., Guillot, F., et al. (2020) Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation versus Insulin-Only Closed-Loop System Compared with a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial. Diabetes Care, 43, 2721-2729. https://doi.org/10.2337/dc19-2267
|
[163]
|
El-Khatib, F.H., Balliro, C., Hillard, M.A., Magyar, K.L., Ekhlaspour, L., Sinha, M., Mondesir, D., Esmaeili, A., Hartigan, C., Thompson, M.J., et al. (2017) Home Use of a Bihormonal Bionic Pancreas versus Insulin Pump Therapy in Adults with Type 1 Diabetes: A Multicentre Randomised Crossover Trial. The Lancet, 389, 369-380. https://doi.org/10.1016/S0140-6736(16)32567-3
|
[164]
|
Peters, T.M. and Haidar, A. (2018) Dual-Hormone Artificial Pancreas: Benefits and Limitations Compared with Single-Hormone Systems. Diabetic Medicine, 35, 450-459. https://doi.org/10.1111/dme.13581
|
[165]
|
Sherr, J.L., Patel, N.S., Michaud, C.I., Palau-Collazo, M.M., Van Name, M.A., Tamborlane, W.V., Cengiz, E., Carria, L.R., Tichy, E.M. and Weinzimer, S.A. (2016) Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner during Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care, 39, 1127-1134. https://doi.org/10.2337/dc16-0089
|
[166]
|
Mathieu, C., Zinman, B., Hemmingsson, J.U., Woo, V., Colman, P., Christiansen, E., Linder, M. and Bode, B. (2016) Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-to-Target Randomized Trial. Diabetes Care, 39, 1702-1710. https://doi.org/10.2337/dc16-0691
|
[167]
|
Dejgaard, T.F., Frandsen, C.S., Hansen, T.S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A.K., Holst, J.J., Tarnow, L., et al. (2016) Efficacy and Safety of Liraglutide for Overweight Adult Patients with Type 1 Diabetes and Insufficient Glycaemic Control (Lira-1): A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet Diabetes & Endocrinology, 4, 221-232. https://doi.org/10.1016/S2213-8587(15)00436-2
|
[168]
|
Riddell, M.C., Gallen, I.W., Smart, C.E., Taplin, C.E., Adolfsson, P., Lumb, A.N., Kowalski, A., Rabasa-Lhoret, R., McCrimmon, R.J., Hume, C., et al. (2017) Exercise Management in Type 1 Diabetes: A Consensus Statement. The Lancet Diabetes & Endocrinology, 5, 377-390. https://doi.org/10.1016/S2213-8587(17)30014-1
|
[169]
|
Ploug, T., Galbo, H. and Richter, E.A. (1984) Increased Muscle Glucose Uptake during Contractions: No Need for Insulin. The American Journal of Physiology, 247, E726-E731. https://doi.org/10.1152/ajpendo.1984.247.6.E726
|
[170]
|
Hawley, J.A. and Lessard, S.J. (2008) Exercise Training-Induced Improvements in Insulin Action. Acta Physiologica, 192, 127-135. https://doi.org/10.1111/j.1748-1716.2007.01783.x
|
[171]
|
Jacobs, P.G., El Youssef, J., Reddy, R., Resalat, N., Branigan, D., Condon, J., Preiser, N., Ramsey, K., Jones, M., Edwards, C., et al. (2016) Randomized Trial of a Dual-Hormone Artificial Pancreas with Dosing Adjustment during Exercise Compared with No Adjustment and Sensor-Augmented Pump Therapy. Diabetes, Obesity & Metabolism, 18, 1110-1119. https://doi.org/10.1111/dom.12707
|
[172]
|
Resalat, N., El Youssef, J., Reddy, R. and Jacobs, P.G. (2016) Design of a Dual-Hormone Model Predictive Control for Artificial Pancreas with Exercise Model. 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Orlando, FL, 16-20 August 2016, 2270-2273. https://doi.org/10.1109/EMBC.2016.7591182
|
[173]
|
Jayawardene, D.C., McAuley, S.A., Horsburgh, J.C., Gerche, A., Jenkins, A.J., Ward, G.M., MacIsaac, R.J., Roberts, T.J., Grosman, B., et al. (2017) Closed-Loop Insulin Delivery for Adults with Type 1 Diabetes Undertaking High-Intensity Interval Exercise versus Moderate-Intensity Exercise: A Randomized, Crossover Study. Diabetes Technology & Therapeutics, 19, 340-348. https://doi.org/10.1089/dia.2016.0461
|
[174]
|
Breton, M.D., Brown, S.A., Karvetski, C.H., Kollar, L., Topchyan, K.A., Anderson, S.M. and Kovatchev, B.P. (2014) Adding Heart Rate Signal to a Control-to-Range Artificial Pancreas System Improves the Protection against Hypoglycemia during Exercise in Type 1 Diabetes. Diabetes Technology & Therapeutics, 16, 506-511. https://doi.org/10.1089/dia.2013.0333
|
[175]
|
Lee, M.H., Paldus, B., Krishnamurthy, B., McAuley, S.A., Shah, R., Jenkins, A.J. and O’Neal, D.N. (2019) The Clinical Case for the Integration of a Ketone Sensor as Part of a Closed Loop Insulin Pump System. Journal of Diabetes Science and Technology, 13, 967-973. https://doi.org/10.1177/1932296818822986
|
[176]
|
Alva, S., Castorino, K., Cho, H. and Ou, J. (2021) Feasibility of Continuous Ketone Monitoring in Subcutaneous Tissue Using a Ketone Sensor. Journal of Diabetes Science and Technology, 15, 768-774. https://doi.org/10.1177/19322968211008185
|
[177]
|
O’Connor, M.R., Carlin, K., Coker, T., Zierler, B. and Pihoker, C. (2019) Disparities in Insulin Pump Therapy Persist in Youth with Type 1 Diabetes Despite Rising Overall Pump Use Rates. Journal of Pediatric Nursing, 44, 16-21. https://doi.org/10.1016/j.pedn.2018.10.005
|
[178]
|
Renard, E., Tubiana-Rufi, N., Bonnemaison-Gilbert, E., Coutant, R., Dalla-Vale, F., Farret, A., Poidvin, A., Bouhours-Nouet, N., Abettan, C., Storey-London, C., et al. (2019) Closed-Loop Driven by Control-to-Range Algorithm Outperforms Threshold-Low-Glucose-Suspend Insulin Delivery on Glucose Control Albeit Not on Nocturnal Hypoglycaemia in Prepubertal Patients with Type 1 Diabetes in a Supervised Hotel Setting. Diabetes, Obesity & Metabolism, 21, 183-187. https://doi.org/10.1111/dom.13482
|
[179]
|
American Diabetes Association. Help with Insulin Is a Phone Call Away. https://insulinhelp.org
|
[180]
|
Shafie, A.A., Ng, C.H., Tan, Y.P. and Chaiyakunapruk, N. (2017) Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. Pharmacoeconomics, 35, 141-162. https://doi.org/10.1007/s40273-016-0456-2
|
[181]
|
Walker, A.F., Hood, K.K., Gurka, M.J., Filipp, S.L., Anez-Zabala, C., Cuttriss, N., Haller, M.J., Roque, X., Naranjo, D., Aulisio, G., et al. (2021) Barriers to Technology Use and Endocrinology Care for Underserved Communities with Type 1 Diabetes. Diabetes Care, 44, 1480-1490. https://doi.org/10.2337/dc20-2753
|
[182]
|
Sumnik, Z., Szypowska, A., Iotova, V., Bratina, N., Cherubini, V., Forsander, G., Jali, S., Raposo, J.F., Stipančic, G., Vazeou, A., et al. (2019) Persistent Heterogeneity in Diabetes Technology Reimbursement for Children with Type 1 Diabetes: The SWEET Perspective. Pediatric Diabetes, 20, 434-443. https://doi.org/10.1111/pedi.12833
|
[183]
|
Lipman, T.H., Smith, J.A., Patil, O., Willi, S.M. and Hawkes, C.P. (2021) Racial Disparities in Treatment and Outcomes of Children with Type 1 Diabetes. Pediatric Diabetes, 22, 241-248. https://doi.org/10.1111/pedi.13139
|
[184]
|
Fantasia, K.L., Wirunsawanya, K., Lee, C. and Rizo, I. (2021) Racial Disparities in Diabetes Technology Use and Outcomes in Type 1 Diabetes in a Safety-Net Hospital. Journal of Diabetes Science and Technology, 15, 1010-1017. https://doi.org/10.1177/1932296821995810
|
[185]
|
Walker, A.F., Haller, M.J., Gurka, M.J., Morris, H.L., Bruggeman, B., Miller, K., Foster, N., Anez Zabala, C. and Schatz, D.A. (2020) Addressing Health Disparities in Type 1 Diabetes through Peer Mentorship. Pediatric Diabetes, 21, 120-127. https://doi.org/10.1111/pedi.12935
|
[186]
|
Peters, A.L. and Garg, S.K. (2020) The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth. Diabetes Technology & Therapeutics, 22, 449-453. https://doi.org/10.1089/dia.2020.0187
|